In Vitro Cytotoxicity Pre-Test: Technical Principles, Methods, and ISO 10993-5 Compliance

The in vitro cytotoxicity pre-test is a rapid, cell-culture-based screening procedure used to identify potentially toxic materials or extracts before formal biocompatibility testing is initiated. Performed in accordance with ISO 10993-5 and ISO 10993-12, this preliminary evaluation enables medical device manufacturers to select safer candidate materials, optimize extraction parameters, and reduce the risk of failure during full regulatory studies. This article explains the technical principles, sample requirements, test methods, and practical applications of in vitro cytotoxicity pre-testing.

Technical Overview

The in vitro cytotoxicity pre-test is an early-stage, laboratory-scale evaluation designed to detect harmful effects of medical device materials, extracts, or process-related residues on cultured mammalian cells. It serves as a feasibility and risk-screening step performed prior to formal, study-plan-driven cytotoxicity testing conducted for regulatory submissions. The technical basis of the test is defined in ISO 10993-5 (Tests for in vitro cytotoxicity), while sample preparation and extraction conditions follow ISO 10993-12 (Sample preparation and reference materials). The corresponding Chinese national standard series, GB/T 16886.5, adopts the same technical framework.

During a pre-test, materials are brought into contact with a well-characterized mammalian cell line—most commonly L929 mouse fibroblasts, which are the preferred cell type in ISO 10993-5:2009—through direct contact, indirect contact, or extract (elution) exposure. Cell responses are then evaluated either quantitatively, by measuring metabolic viability using colorimetric or fluorometric assays, or qualitatically, by microscopic grading of cell morphology and lysis on a 0-to-4 reactivity scale. Under the quantitative approach, a test article is considered to have cytotoxic potential when cell viability falls below 70% of the blank control. The pre-test format allows manufacturers to iterate quickly on materials and processes at low cost, before committing to the longer timelines and larger sample quantities required for full biocompatibility studies.

Testing Samples

Finished Medical Devices and Device Components

Catheters, tubing sets, syringes, infusion sets, cannulae, implants, electrodes, and other patient-contacting components can be screened as whole units or as representative coupons cut from the finished product.

Polymer, Elastomer, and Metal Materials

Granules, sheets, films, cured slabs, and molded coupons of candidate polymers, silicone elastomers, thermoplastic polyurethanes, stainless steels, titanium alloys, and other raw materials are frequently submitted for early cytotoxicity screening during material selection.

Dental Materials

Composite resins, adhesives, cements, impression materials, and denture base resins are evaluated because their monomers and curing by-products may leach into adjacent tissues.

Wound Dressings and Skin-Contact Products

Hydrogels, hydrocolloids, foams, alginate dressings, adhesive patches, and transdermal systems are tested to confirm that released substances do not impair cell viability.

Coatings, Adhesives, Inks, and Processing Aids

Surface coatings, sterilization residues, cleaning agents, mold-release agents, printing inks, and solvent residues are common sources of cytotoxic leachables and are appropriate targets for pre-test screening.

Pharmaceutical Packaging and Combination Products

Primary packaging materials, container closure systems, and drug-device combination products are screened to identify interactions between contacting materials and biological systems.

Testing Items

A typical in vitro cytotoxicity pre-test program may include the following evaluations, selected according to the nature of the sample and the intended clinical use:

• Extract-based (elution) cytotoxicity testing with quantitative viability measurement
• Direct contact cytotoxicity testing for surface-evaluating materials
• Indirect contact cytotoxicity testing using agar diffusion or filter diffusion methods
• Cell viability and metabolic activity measurement using MTT, XTT, WST-8, neutral red uptake, or resazurin (Alamar Blue) endpoints
• Qualitative microscopic grading of cell morphology, vacuolization, detachment, and lysis
• Extraction ratio, extraction vehicle, and extraction condition optimization studies
• Dilution series testing to characterize dose-response behavior of cytotoxic extracts
• Assessment of test-article interference with the chosen viability endpoint (color, turbidity, or redox interference)

Testing Methods

Extract Test (MEM Elution Method)

The test article is extracted in a polar vehicle such as serum-supplemented Minimum Essential Medium (MEM), physiological saline, or a non-polar vehicle such as sesame oil. Extracts are then applied to confluent L929 cell monolayers, typically for 24 to 48 hours of exposure, after which viability is measured. This is the most widely used method in ISO 10993-5 and is suitable for almost all device materials.

Direct Contact Method

A specimen of defined area or mass is placed directly onto the cell monolayer, and cytotoxicity is assessed after 24 to 48 hours by morphological grading and, where applicable, quantitative assay. This method is particularly informative for materials that release low levels of substances or exert physical effects on cells.

Indirect Contact Method (Agar Diffusion and Filter Diffusion)

In the agar overlay method, a thin agar layer protects the monolayer while allowing diffusible leachables to reach the cells. In the filter diffusion method, cells grown on a cellulose acetate membrane are exposed to the test material. Both methods are well suited to evaluating elastomers, sealants, and materials with planar geometry.

Sample Preparation and Extraction Conditions

Extraction is performed under aseptic conditions using standardized ratios defined in ISO 10993-12, such as 3 cm²/mL or 6 cm²/mL depending on material thickness, and 0.1 to 0.2 g/mL for irregular or porous materials. The standard extraction condition is 37 ± 1 °C for 24 ± 2 hours, with alternative conditions such as 37 °C for 72 hours, 50 °C for 72 hours, 70 °C for 24 hours, or 121 °C for 1 hour used when justified to simulate exaggerated or clinical-use exposure.

Controls and Acceptance Criteria

Each assay includes a negative control (typically high-density polyethylene reference material), a blank extraction vehicle control, and a positive control such as latex material, organotin-containing rubber reference materials, or a detergent like Triton X-100, depending on the method. The test is considered valid only when controls perform as expected. Quantitative results are interpreted against the ISO 10993-5 threshold: viability greater than or equal to 70% of the blank control indicates no significant cytotoxic potential, while lower values trigger dilution series testing or material reformulation.

Applications

In vitro cytotoxicity pre-testing is applied at multiple stages of the medical device lifecycle:

• Early research and development screening of candidate materials and formulations before tooling or scale-up investment
• Comparative evaluation of alternative suppliers, resin grades, curing systems, or sterilization methods (ethylene oxide, gamma, e-beam, steam)
• Assessment of process changes, formulation changes, or changes in cleaning and packaging that may alter leachable profiles
• Optimization of extraction ratios and vehicles ahead of formal ISO 10993-5 studies, reducing the risk of repeat testing
• Screening of extractable and leachable substances identified from chemical characterization in support of a biological evaluation plan under ISO 10993-1
• Internal quality control and lot-to-lot consistency checks for high-risk material lots
• Feasibility verification before submitting samples to accredited third-party laboratories for full biocompatibility test batteries

FAQ

What is the difference between a pre-test and a formal cytotoxicity test?

A pre-test is an internal, small-scale screening run used for decision-making during development, whereas a formal test is executed under a controlled study plan, often in a GLP-compliant environment, and documented to support regulatory submissions. The underlying methods and ISO 10993-5 criteria are the same, but the documentation, quality system oversight, and data traceability requirements differ.

Which cell line is used for the test?

L929 mouse connective tissue fibroblasts are the preferred cell line specified in ISO 10993-5:2009. V79 hamster lung fibroblasts and BALB/c 3T3 mouse fibroblasts are also accepted alternatives when scientifically justified.

How much sample is required?

Sample requirements depend on the extraction ratio. As a practical guide, laboratories typically request 1 to 4 grams of material or 6 to 12 square centimeters of surface area per extraction condition, with additional material needed when multiple vehicles or extraction temperatures are evaluated.

What is the pass criterion?

Under the quantitative MTT-based approach, a sample is considered non-cytotoxic when mean cell viability is at least 70% of the blank control. Under the qualitative approach, reactivity grades of 0 (none) to 4 (severe) are assigned, with grades 0 to 1 generally regarded as acceptable and higher grades indicating the need for follow-up evaluation.

How long does a pre-test take?

Because pre-tests use the same cell culture workflows as formal studies but with streamlined documentation, typical turnaround is 5 to 10 working days from cell seeding to data reporting, depending on method selection and whether dilution series testing is required.

Can pre-test results be used for regulatory submission?

Pre-test results are primarily intended for internal risk management and study optimization. For submission purposes, most regulatory expectations call for formal cytotoxicity studies with full documentation performed by qualified laboratories; pre-test data can, however, strengthen the scientific rationale within a biological evaluation file prepared under ISO 10993-1.

What should be done if a sample shows cytotoxicity?

A cytotoxic result should trigger root-cause investigation, such as identifying the offending leachable through chemical characterization, evaluating dilution series to establish the cytotoxic threshold, testing alternative materials or sterilization modes, or modifying post-curing and cleaning processes, followed by retesting to confirm improvement.